Investor activists win again and persuade Endo to catalog opioid risks

Amid complaints from shareholder activists, Endo International (ENDP) has issued a report about the risks of selling opioid painkillers and agreed to expand a so-called clawback policy for executive compensation when negligence occurs. The company will also beef up disclosure of its lobbying efforts.

The move is the latest victory for Investors for Opioid Accountability, a coalition of institutional investors that has been pushing drug makers, wholesalers, and pharmacies to take steps to rein in the opioid crisis by changing business practices. Previously, Assertio Therapeutics (ASRT) agreed to monitor opioid risks, but Endo is the first large drug maker to take a more comprehensive step.

“In a larger sense, this report is an important bellwether,”  Illinois State Treasurer Michael Frerichs said in a statement. “More and more companies with opioid risk exposures are heeding the calls of investors to implement strong board oversight structures, accountability systems, and robust reporting processes.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In